Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (971) 971
Book Review (131) 131
Publication (47) 47
Book Chapter (2) 2
Conference Proceeding (2) 2
Magazine Article (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (857) 857
humans (667) 667
aminobutyrates - therapeutic use (537) 537
male (399) 399
animals (351) 351
female (298) 298
tetrazoles - therapeutic use (234) 234
aminobutyrates - pharmacology (211) 211
middle aged (203) 203
heart failure - drug therapy (196) 196
angiotensin receptor antagonists - therapeutic use (177) 177
rats (166) 166
adult (162) 162
pharmacology & pharmacy (156) 156
heart failure (144) 144
neprilysin - antagonists & inhibitors (138) 138
aged (121) 121
cardiac & cardiovascular systems (112) 112
mice (96) 96
aminobutyrates - metabolism (92) 92
abridged index medicus (91) 91
heart failure - physiopathology (88) 88
aminobutyrates - adverse effects (84) 84
time factors (84) 84
aminobutyrates - administration & dosage (83) 83
treatment outcome (83) 83
clinical trials as topic (80) 80
lcz696 (74) 74
enalapril (72) 72
angiotensin-converting enzyme inhibitors - therapeutic use (65) 65
brain - metabolism (65) 65
adolescent (61) 61
neprilysin (61) 61
tetrazoles - adverse effects (61) 61
aminobutyrates (60) 60
valsartan (59) 59
enalapril - therapeutic use (55) 55
angiotensin (54) 54
in vitro techniques (54) 54
mortality (54) 54
tetrazoles - pharmacology (54) 54
dose-response relationship, drug (52) 52
baclofen - therapeutic use (50) 50
child (49) 49
dentistry (48) 48
neurosciences (48) 48
hypertension (45) 45
medicine, general & internal (43) 43
gamma-aminobutyric acid - metabolism (42) 42
hypertension - drug therapy (42) 42
chronic disease (41) 41
natriuretic peptides (41) 41
analysis (40) 40
angiotensin receptor antagonists - adverse effects (40) 40
double-blind (39) 39
heart-failure (39) 39
neprilysin inhibition (39) 39
stroke volume (39) 39
drug evaluation (38) 38
sacubitril/valsartan (38) 38
dental caries - therapy (37) 37
angiotensin receptor antagonists - pharmacology (36) 36
double-blind method (36) 36
aminobutyrates - pharmacokinetics (35) 35
drug therapy (34) 34
rats, sprague-dawley (34) 34
renin-angiotensin system - drug effects (34) 34
stroke volume - drug effects (34) 34
care and treatment (33) 33
tetrazoles - administration & dosage (33) 33
dental cavity preparation - methods (32) 32
gamma-aminobutyric acid - therapeutic use (32) 32
valsartan - therapeutic use (32) 32
heart failure - mortality (31) 31
preserved ejection fraction (31) 31
toxicology (31) 31
aminobutyrates - analysis (30) 30
angiotensin ii type 1 receptor blockers - therapeutic use (30) 30
drug combinations (30) 30
enzymes (30) 30
muscle spasticity - drug therapy (30) 30
aminobutyrates - chemistry (29) 29
cats (29) 29
randomized controlled trials as topic (29) 29
sacubitril (29) 29
antihypertensive agents - therapeutic use (28) 28
blood pressure - drug effects (28) 28
cardiac patients (28) 28
child, preschool (28) 28
excitatory amino acid agonists - pharmacology (28) 28
heart failure - diagnosis (28) 28
old medline (28) 28
pharmacology (28) 28
schizophrenia - drug therapy (28) 28
glutamate (27) 27
placebos (27) 27
receptors, metabotropic glutamate - agonists (27) 27
risk factors (27) 27
brain - drug effects (26) 26
research (26) 26
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (749) 749
German (52) 52
Italian (52) 52
Russian (27) 27
French (23) 23
Japanese (22) 22
Portuguese (12) 12
Spanish (9) 9
Polish (7) 7
Czech (4) 4
Dutch (4) 4
Swedish (4) 4
Ukrainian (2) 2
Bulgarian (1) 1
Chinese (1) 1
Danish (1) 1
Finnish (1) 1
Hebrew (1) 1
Norwegian (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure with Reduced Ejection Fraction: Insights from Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial
by Kristensen, Søren L and Preiss, David and Jhund, Pardeep S and Squire, Iain and Cardoso, Jose Silva and Merkely, Bela and Martinez, Felipe and Starling, Randall C and Desai, Akshay S and Lefkowitz, Martin P and Rizkala, Adel R and Rouleau, Jean L and Shi, Victor C and Solomon, Scott D and Swedberg, Karl and Zile, Michael R and McMurray, John J.V and Packer, Milton and PARADIGM-HF Investigators and Committees and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
Circulation: Heart Failure, ISSN 1941-3289, 01/2016, Volume 9, Issue 1
Background The prevalence of pre-diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known. We... 
heart failure | Clinical trial | diabetes mellitus | prognosis | treatment outcome | clinical trial | CARDIAC & CARDIOVASCULAR SYSTEMS | PREDICTOR | TOLERANCE | HEMOGLOBIN A(1C) | HOSPITALIZATION | INHIBITION | A1C | INSULIN-RESISTANCE | GLUCOSE | DYSFUNCTION | OUTCOMES | Diabetes Mellitus - blood | Single-Blind Method | Prevalence | Prospective Studies | Ventricular Function, Left | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Heart Failure - physiopathology | Aminobutyrates - adverse effects | Male | Heart Failure - blood | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Enalapril - adverse effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Time Factors | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Female | Heart Failure - diagnosis | Diabetes Mellitus - diagnosis | Diabetes Mellitus - mortality | Prediabetic State - epidemiology | Heart Failure - mortality | Prediabetic State - blood | Risk Assessment | Comorbidity | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Biomarkers - blood | Heart Failure - drug therapy | Prediabetic State - mortality | Prediabetic State - diagnosis | Stroke Volume | Disease-Free Survival | Diabetes Mellitus - epidemiology | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Blood Glucose - metabolism | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Angiotensin Receptor Antagonists - adverse effects | Index Medicus | 10093 | 10150 | 10094 | Original | glucose | hospitalization | inhibition | Klinisk medicin | dysfunction | Clinical Medicine | a1c | insulin-resistance | hemoglobin a(1c) | Cardiovascular System & Cardiology | predictor | cardiovascular risk | tolerance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
by McMurray, John J.V and Packer, Milton and Desai, Akshay S and Gong, Jianjian and Lefkowitz, Martin P and Rizkala, Adel R and Rouleau, Jean L and Shi, Victor C and Solomon, Scott D and Swedberg, Karl and Zile, Michael R and PARADIGM-HF Investigators Comm and PARADIGM-HF Investigators and Committees and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 11, pp. 993 - 1004
The angiotensin receptor–neprilysin inhibitor LCZ696 was compared with the ACE inhibitor enalapril in patients with advanced heart failure. LCZ696 was superior... 
NEUTRAL ENDOPEPTIDASE INHIBITION | NATRIURETIC-PEPTIDE | MORTALITY | SURVIVAL | MEDICINE, GENERAL & INTERNAL | CONVERTING ENZYME-INHIBITION | MORBIDITY | EJECTION FRACTION | DOUBLE-BLIND | RANDOMIZED-TRIAL | RECEPTOR | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Aminobutyrates - adverse effects | Hospitalization - statistics & numerical data | Male | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Enalapril - adverse effects | Heart Failure - drug therapy | Stroke Volume | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Neprilysin - antagonists & inhibitors | Female | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Angiotensin Receptor Antagonists - adverse effects | Heart Failure - mortality | Heart failure | Enalapril | Patient outcomes | Angiotensin | Enalaprilat | Dosage and administration | Research | Drug therapy | Enzymes | Statistical analysis | Mortality | Angioedema | Hypotension | Cough | Studies | Hyperkalemia | Death | Neprilysin | Heart diseases | Index Medicus | Abridged Index Medicus | Klinisk medicin | Medicine | Clinical Medicine | General & Internal
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients with and Without Atrial Fibrillation
by Kristensen, Søren Lund and Jhund, Pardeep S and Mogensen, Ulrik M and Rørth, Rasmus and Abraham, William T and Desai, Akshay and Dickstein, Kenneth and Rouleau, Jean L and Zile, Michael R and Swedberg, Karl and Packer, Milton and Solomon, Scott D and Køber, Lars and McMurray, John J.V and PARADIGM-Hf & ATMOSPHERE and PARADIGM-HF and ATMOSPHERE Committees and Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
Circulation: Heart Failure, ISSN 1941-3289, 10/2017, Volume 10, Issue 10
BACKGROUND: Patients with heart failure (HF) and atrial fibrillation (AF) have higher circulating levels of NT-proBNP (N-terminal pro-B-type natriuretic... 
heart failure | natriuretic peptide, brain | atrial fibrillation | TRIAL | NEPRILYSIN | CARDIAC & CARDIOVASCULAR SYSTEMS | INHIBITION | ALISKIREN | ENALAPRIL | Prognosis | Humans | Middle Aged | Heart Failure - physiopathology | Hospitalization - statistics & numerical data | Male | Heart Failure - blood | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Case-Control Studies | Peptide Fragments - blood | Cardiovascular Diseases - mortality | Female | Natriuretic Peptide, Brain - blood | Heart Failure - complications | Fumarates - therapeutic use | Atrial Fibrillation - complications | Amides - therapeutic use | Antihypertensive Agents - therapeutic use | Heart Failure - drug therapy | Atrial Fibrillation - blood | Stroke Volume | Tetrazoles - therapeutic use | Aged | Angiotensin Receptor Antagonists - therapeutic use | Cohort Studies | Index Medicus | Cardiovascular Diseases/mortality | Atrial Fibrillation/blood/complications | Amides/therapeutic use | Klinisk medicin | Tetrazoles/therapeutic use | Fumarates/therapeutic use | Aminobutyrates/therapeutic use | Hospitalization/statistics & numerical data | Angiotensin Receptor Antagonists/therapeutic use | Heart Failure/blood/complications/drug therapy/physiopathology | Natriuretic Peptide | Antihypertensive Agents/therapeutic use | Enalapril/therapeutic use | Brain/blood | Clinical Medicine | Peptide Fragments/blood
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
by McMurray, John J. V and Packer, Milton and Desai, Akshay S and Gong, Jianjian and Lefkowitz, Martin and Rizkala, Adel R and Rouleau, Jean L and Shi, Victor C and Solomon, Scott D and Swedberg, Karl and Zile, Michael R and PARADIGM-HF Comm Investigators and PARADIGM-HF Committees Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
European Journal of Heart Failure, ISSN 1388-9842, 07/2014, Volume 16, Issue 7, pp. 817 - 825
Aim To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine... 
Heart failure | Renin–angiotensin system | Neutral endopeptidase | Natriuretic peptides | Renin-angiotensin system | CARDIAC & CARDIOVASCULAR SYSTEMS | GUIDELINES | CARDIAC-RESYNCHRONIZATION THERAPY | RANDOMIZED CONTROLLED-TRIAL | METOPROLOL | NATRIURETIC PEPTIDE SYSTEM | CARVEDILOL | INHIBITION | TASK-FORCE | EJECTION FRACTION | ROSUVASTATIN | Humans | Middle Aged | Heart Failure - physiopathology | Male | Treatment Outcome | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | Patient Selection | Randomized Controlled Trials as Topic | Stroke Volume | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Quality of Life | Diuretics - therapeutic use | Female | Tetrazoles - therapeutic use | Aged | Platelet Aggregation Inhibitors - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Natriuretic Peptide, Brain - blood | Adrenergic beta-Antagonists - therapeutic use | Heart Failure - mortality | Index Medicus | Treatments | Clinical Medicine | heart failure | treatment | Klinisk medicin | prognosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
by Desai, Akshay S and McMurray, John J.V and Packer, Milton and Swedberg, Karl and Rouleau, Jean L and Chen, Fabian and Gong, Jianjian and Rizkala, Adel R and Brahimi, Abdel and Claggett, Brian and Finn, Peter V and Hartley, Loren Howard and Liu, Jiankang and Lefkowitz, Martin and Shi, Victor and Zile, Michael R and Solomon, Scott D and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
European Heart Journal, ISSN 0195-668X, 08/2015, Volume 36, Issue 30, pp. 1990 - 1997
Aims The angiotensin-receptor-neprilysin inhibitor (ARNI) LCZ696 reduced cardiovascular deaths and all-cause mortality compared with enalapril in patients with... 
Heart failure | Angiotensin-receptor blocker | Pharmacotherapy | Clinical trial | Neprilysin inhibition | Mortality | SURVIVAL | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | LISINOPRIL | CONVERTING-ENZYME-INHIBITORS | TRIAL | CARDIAC-RESYNCHRONIZATION | MORBIDITY | CANDESARTAN | DYSFUNCTION | Prospective Studies | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Cause of Death | Heart Failure - drug therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Female | Tetrazoles - therapeutic use | Aged | Angiotensin Receptor Antagonists - therapeutic use | Heart Failure - mortality | Index Medicus | MORTALITY | Kardiologi | Cardiac & Cardiovascular Systems | Cardiac and Cardiovascular Systems
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure
by Packer, M and McMurray, J.J and Desai, A.S and Gong, J and Lefkowitz, M.P and Rizkala, A.R and Rouleau, J.L and Shi, V.C and Solomon, S.D and Swedberg, K and Zile, M and Andersen, K and Arango, J.L and Arnold, J.M and Belohlavek, J and Bohm, M and Boytsov, S and Burgess, L.J and Cabrera, W and Calvo, C and Chen, C.H and Dukat, A and Duarte, Y.C and Erglis, A and Fu, M and Gomez, E and Gonzalez-Medina, A and Hagege, A.A and Huang, J and Katova, T and Kiatchoosakun, S and Kim, K.S and Kozan, O and Llamas, E.B and Martinez, F and Merkely, B and Mendoza, I and Mosterd, A and Negrusz-Kawecka, M and Peuhkurinen, K and Ramires, F.J and Refsgaard, J and Rosenthal, A and Senni, M and Sibulo, A.S., Jr and Silva-Cardoso, J and Squire, I.B and Starling, R.C and Teerlink, J.R and Vanhaecke, J and Vinereanu, D and Wong, R.C and Bellersen, L and PARADIGM-HF Investigators and PARADIGM-HF Investigators and Coordinators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
Circulation, ISSN 0009-7322, 2015, Volume 131, Issue 1, pp. 54 - 61
BACKGROUND: Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events.... 
heart failure | Receptors | receptors, angiotensin | neprilysin | Angiotensin | MORTALITY | CONVERTING ENZYME | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | NEUTRAL ENDOPEPTIDASE | ADRENOMEDULLIN | NATRIURETIC-PEPTIDE | MILD SYMPTOMS | TRIAL | LEFT-VENTRICULAR DYSFUNCTION | PERIPHERAL VASCULAR DISEASE | BRADYKININ | Double-Blind Method | Humans | Risk Factors | Heart Failure - physiopathology | Kaplan-Meier Estimate | Stroke Volume - physiology | Survivors | Treatment Outcome | Biomarkers - blood | Heart Failure - blood | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Disease Progression | Heart Failure - drug therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Neprilysin - antagonists & inhibitors | Peptide Fragments - blood | Troponin - blood | Tetrazoles - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Natriuretic Peptide, Brain - blood | Heart failure | Symptomatology | Usage | Care and treatment | Enalapril | Analysis | Enalaprilat | Angiotensin II receptor blockers | Clinical trials | Dosage and administration | Comparative analysis | Risk factors | Index Medicus | Abridged Index Medicus | neprilysin receptors | angiotensin | Clinical Medicine | Klinisk medicin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights